Open AccessAdoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States
Author(s) -
Helen Parsons,
Quyen D. Chu,
Jordan J. Karlitz,
Jennifer Stevens,
Linda C. Harlan
Publication year - 2017
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 2235-1795
pISSN - 1664-5553
DOI - 10.1159/000473862
Subject(s) - sorafenib , medicine , hepatocellular carcinoma , oncology , hazard ratio , proportional hazards model , population , cancer , confidence interval , environmental health
The adoption of sorafenib into oncology practice as a first-line systemic treatment for advanced hepatocellular carcinoma (HCC) is not well understood. We examined sorafenib use since Food and Drug Administration (FDA) approval in 2007 and associated survival for individuals diagnosed with advanced HCC, conducting a population-based evaluation of treatment patterns and outcomes for this newly approved drug in the US over time.